Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

Danielord Aug. 11 at 10:23 AM

$ABCL give me 10 again i want short more

0 · Reply

tiddyy Aug. 11 at 9:27 AM

$ABCL And this is why I believe that the valuation will continue to grow, ABCL635 walked so all their other programs can run. And keep in mind they are planning on discovering more molecules year by year

0 · Reply

tiddyy Aug. 11 at 9:25 AM

$ABCL I think a sleeper catalyst is the announcement of ABCL688’s target, which Phase 1 is planned for 2027 It’s another program that can target GPCR or Ion channels, information is not given yet as what specific target, all we know it’s an autoimmune-disease program I will be very curious to know what it is, perhaps it’s something even larger in terms of valuation compared to ABCL635 If it’s another validated GPCR with a even larger market, well god help anyone trying to short this in the future I am assuming we will hear news soon, market not giving these programs their flowers properly

0 · Reply

Danielord Aug. 11 at 9:08 AM

$ABCL free short hahaha i said it hahahah naiv bulls hahahaha

1 · Reply

lustiger Aug. 11 at 9:00 AM

$ABCL analyst's price targets back to levels of 2022 and 2023. This will be one catalyst. The other probably is the reduction of short positions.

0 · Reply

Chebsmcgee Aug. 11 at 8:00 AM

$ABCL :)

0 · Reply

lustiger Aug. 11 at 6:23 AM

$ABCL 650 mio cash and 50 mio spent per quarter. Got enough for 3 years, as stated in ER.

0 · Reply

mikesterz7 Aug. 11 at 6:19 AM

$ABCL AbCellera stock hit a three-year high after positive Phase 2 results for ABCL635 showed an 83% reduction in hot-flash frequency.

1 · Reply

DataClown Aug. 11 at 6:08 AM

$ABCL Bullish on the platform, but the 6.9-month cash runway means shareholders are one press release away from a dilution event that will test their conviction the hard way.

1 · Reply

tiddyy Aug. 11 at 5:23 AM

$ABCL Price target increases are cool and all, but let’s see those institutional buys which I expect to be heavy 😉

0 · Reply

AbCellera price target raised to $25 from $13 at JonesResearch

Aug 10, 2026, 8:00 AM EDT - 22 hours ago

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 7:30 AM EDT - 22 hours ago

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 22 hours ago

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 22 hours ago

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:23 AM EDT - 23 hours ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:13 AM EDT - 23 hours ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

2026-08-10T11:11:27.000Z - 23 hours ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

Aug 10, 2026, 7:00 AM EDT - 23 hours ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 7, 2026, 4:30 PM EDT - 3 days ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

2026-08-06T12:20:50.000Z - 4 days ago

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:12:02.000Z - 4 days ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

Aug 5, 2026, 5:00 PM EDT - 5 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 days ago

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 days ago

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 days ago

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 5 days ago

AbCellera Reports Q2 2026 Business Results

2026-07-29T11:27:06.000Z - 12 days ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

Jul 29, 2026, 7:00 AM EDT - 12 days ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

2026-07-09T21:29:02.000Z - 4 weeks ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 4 weeks ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 4 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

2026-07-06T13:15:29.000Z - 5 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL

Jul 6, 2026, 9:00 AM EDT - 5 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 7 weeks ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 7 weeks ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 2 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 3 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 3 months ago

AbCellera price target raised to $8 from $7 at Stifel

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 3 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 3 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 3 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 4 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 5 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 6 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 7 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation

Jan 12, 2026, 9:00 AM EST - 7 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 8 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 8 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 8 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 2 years ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 2 years ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 2 years ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in September

Danielord Aug. 11 at 10:23 AM

$ABCL give me 10 again i want short more

0 · Reply

tiddyy Aug. 11 at 9:27 AM

0 · Reply

tiddyy Aug. 11 at 9:25 AM

0 · Reply

Danielord Aug. 11 at 9:08 AM

$ABCL free short hahaha i said it hahahah naiv bulls hahahaha

1 · Reply

lustiger Aug. 11 at 9:00 AM

$ABCL analyst's price targets back to levels of 2022 and 2023. This will be one catalyst. The other probably is the reduction of short positions.

0 · Reply

Chebsmcgee Aug. 11 at 8:00 AM

$ABCL :)

0 · Reply

lustiger Aug. 11 at 6:23 AM

$ABCL 650 mio cash and 50 mio spent per quarter. Got enough for 3 years, as stated in ER.

0 · Reply

mikesterz7 Aug. 11 at 6:19 AM

$ABCL AbCellera stock hit a three-year high after positive Phase 2 results for ABCL635 showed an 83% reduction in hot-flash frequency.

1 · Reply

DataClown Aug. 11 at 6:08 AM

$ABCL Bullish on the platform, but the 6.9-month cash runway means shareholders are one press release away from a dilution event that will test their conviction the hard way.

1 · Reply

tiddyy Aug. 11 at 5:23 AM

$ABCL Price target increases are cool and all, but let’s see those institutional buys which I expect to be heavy 😉

0 · Reply

tiddyy Aug. 11 at 5:12 AM

$ABCL I can’t find the Truist article for the re rating that shows $30, but this is the latest re rate I found from yesterday, which was Jones Trading, target raised to $25 from $13 https://www.tipranks.com/news/the-fly/abcellera-price-target-raised-to-25-from-13-at-jonesresearch-thefly-news

0 · Reply

KernelMarkets Aug. 11 at 4:19 AM

$CLSK $ETH $HIMS $BW $ABCL CleanSpark benefits from Bitcoin-mining economics, Ethereum continues expanding blockchain utility, Hims & Hers benefits from digital-health adoption, BW remains tied to nuclear and industrial opportunities, and AbCellera advances AI-assisted drug discovery. I'm watching crypto economics, customer growth, nuclear demand, and biotech milestones.

0 · Reply

GoldenGamma Aug. 11 at 3:43 AM

$XRP $ABCL $AMC $ONDS $TTD XRP focuses on blockchain-based payments, AbCellera advances AI-assisted drug discovery, AMC remains highly speculative, Ondas develops autonomous and wireless systems, and The Trade Desk benefits from digital advertising and connected TV. I'm watching crypto adoption, clinical milestones, liquidity, contract wins, and ad spending.

1 · Reply

IroncladCapital Aug. 11 at 3:35 AM

1 · Reply

TNNStockAnalysisNews Aug. 11 at 3:32 AM

0 · Reply

Stockingtrade Aug. 11 at 3:06 AM

$ABCL Predictions for the analyst re-ratings after today’s readout? I saw $25 from Jones and $30 from Truist - I’m betting more $30-$35 range for the rest.

0 · Reply

ShKumaresan Aug. 11 at 2:33 AM

$ABCL $REPL $ABNB Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? https://stocktwits.com/news-articles/default/equity/why-did-abcl-repl-abnb-stocks-hit-52-week-highs-today/cZoZKg8RJf8

0 · Reply

StocktwitsNews Aug. 11 at 2:31 AM

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? $ABCL $REPL $ABNB https://stocktwits.com/news/equity/markets/why-did-abcl-repl-abnb-stocks-hit-52-week-highs-today/cZoZKg8RJf8

0 · Reply

8008track Aug. 11 at 2:22 AM

$ABCL not sure what your investment plans are but I’ll be here for at least another 5 years. Probably more than 10 yeas. The potential of this company is so big. The result today couldn’t have been any better. I’m so happy to be on this journey with all my fellow longs. And Tradesunion will get his $12 soon. I feel it in my toes.

0 · Reply

Tradeforincome Aug. 11 at 2:11 AM

$ABCL either tank hard tomorrow or shoot up. Just don’t level out in this range. Sitting on $9 calls now. Sold all shares today.

0 · Reply

manojaggarwal Aug. 11 at 12:56 AM

$ABCL on track ; could take two years or less at this rate

0 · Reply

manojaggarwal Aug. 11 at 12:55 AM

$ABCL I got a decent amount but not 10k shares ; should have listened to myself but still doing great

0 · Reply

Market Cap	2.12B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	45,998,500
Avg Vol	7,423,978
Day's Range	N/A - N/A
Shares Out	306.61M
Stochastic %K	86%
Beta	1.20
Analysts	Strong Sell
Price Target	$10.75